

## **Theravance Biopharma to Present at the Leerink Global Healthcare Conference**

GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Renee Gala, Chief Financial Officer, Brett Haumann, Senior Vice President, Clinical Development and Operations, and Frank Pasqualone, Senior Vice President, Operations will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February, 11, 2015, at 3:30 p.m. EST. The conference will be held from February 11-12 in New York at the Waldorf Astoria, New York.

The presentation will be webcast live and can be reached by visiting the Investor Relations section of Theravance Biopharma's website at [www.theravance.com](http://www.theravance.com), under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

### ***About Theravance Biopharma***

The mission of Theravance Biopharma (NASDAQ: TBPH) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV<sup>®</sup> (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S. and Europe for difficult-to-treat infections. TD-4208 is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for COPD. Axelopran (TD-1211) is a potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract -- our core areas of therapeutic focus -- and infectious disease. In addition, we have an economic interest in future payments that may be made by GSK pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of umeclidinium, vilanterol and fluticasone furoate (or the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.

For more information, please visit [www.theravance.com](http://www.theravance.com).

THERAVANCE<sup>®</sup>, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE<sup>®</sup> and VIBATIV<sup>®</sup> are trademarks and/or registered trademarks of the Theravance Biopharma group of companies. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

### ***Contact Information:***

Renee Gala  
Chief Financial Officer  
650-808-4045  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)

Source: Theravance Biopharma

News Provided by Acquire Media